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QUESTIONS
1. Describe generalized non-Herlitz junctional epidermolysis bullosa.
2. What is revertant mosaicism?
3. How did the investigators carry out their study?
4. What were the results and conclusions?
For answers, visit our website or scan the adjacent tag.
It has been said that “nature finds a way,” and, seemingly, so does skin. 
Epidermolysis bullosa is a family of genetic skin defects that results in a 
spectrum of mechanobullous diseases. These diseases impair the qual-
ity of life of patients and their families and, in some instances, affect the 
life span of the patients (Fine, 2001). A variety of gene defects in critical 
proteins, including type XVII collagen (encoded by COL17A1), result 
in skin fragility. Although all skin should be affected by these genetic 
changes, normal areas of skin are often present clinically, often in areas 
that previously exhibited blisters. A process called “revertant mosaicism” 
is thought to cause such normal skin areas. This process may be the 
consequence of additional genetic changes in select cells (or in select areas of skin), leading to a normalization 
of the patient’s phenotype (Kvittingen et al., 1994; Lai-Cheong et al., 2011).
Based on clinical observations of normal skin at previous sites of blisters in patients with generalized non-
Herlitz junctional epidermolysis bullosa, Pasmooij et al., as reported in this issue, studied several patients with 
this condition to determine whether correction of genetic defects had occurred. These studies employed biopsy 
of clinically healthy and clinically affected skin in combination with immunofluorescence microscopy, electron 
microscopy, and laser dissection microscopy to compare tissue and cells from differentially affected skin. The 
researchers found in vivo reversion of the COL17A1 mutation in the four patients who were examined. A vari-
ety of mutations that involved different mechanisms, including mutations affecting gene splicing, were found. 
Through the following questions, we examine this paper in greater detail. For brief answers, please refer to the 
supplementary information online <http://www.nature.com/jid/journal/v132/n5/suppinfo/jid2012115s1.html>.
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